Lineage-associated tumor cell states predict outcome and guide immunotherapeutic target selection in pediatric osteosarcoma

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Osteosarcoma is a highly heterogeneous primary bone malignancy that predominantly affects adolescents and young adults, and robust prognostic biomarkers and effective targeted therapies remain lacking. While single-cell transcriptomics has begun to resolve tumor composition, a tumor cell–intrinsic framework linking transcriptional states to clinical outcome and therapeutic targeting is not established. Here, we present a single-cell transcriptomic analysis of pediatric osteosarcoma, integrating 22 samples across 18 patients spanning six diagnostic, six post-treatment, and ten metastatic lesions profiled using complementary sequencing platforms. Using non-negative matrix factorization, we identify recurrent lineage-associated transcriptional programs that define osteoblastic-like, chondroblastic-like, and fibroblastic-like tumor cell states. These programs show overlapping activity across tumor cells, indicating that tumor cell states are not strictly discrete. Strikingly, combined osteoblastic-like and chondroblastic-like program activity is associated with poorer overall survival, a finding validated across two independent bulk RNA-sequencing cohorts. These tumor cell states are further linked to distinct immune microenvironmental compositions. Mapping candidate immunotherapeutic targets at single-cell resolution reveals variable expression across tumor cell states, supporting state-informed strategies for CAR T cell targeting. Together, our findings establish a tumor cell state framework that links osteosarcoma heterogeneity to clinical outcome and provides a basis for patient stratification and the development of state-informed therapeutic strategies in pediatric osteosarcoma.

Article activity feed